Thursday, Dec 10, 1998
South San Francisco, Calif. -- December 10, 1998 --Genentech, Inc. (NYSE:GNE) today announced the appointment of Stephen George Dilly, M.D., Ph.D., to vice president, Medical Affairs. He will report to Susan Hellmann, M.D., M.P.H., senior vice president of Development and chief medical officer. Dilly is responsible for Genentech's Medical Affairs organization which includes the clinical research and safety, data management/biostatistics, medical information and product experience departments.
"Stephen brings a wealth of experience and enthusiasm to this key position," said Hellmann. "With his broad experience and strong leadership, I am confident that he will help maximize the clinical potential of our product candidates."
Dilly, 39, has held various positions with SmithKline Beecham Pharmaceuticals since 1988. In 1996, he was named the director and vice president of the Neurosciences Therapeutic Unit. Before that, he was director and vice president of the Cardiopulmonary Therapeutic Team, group director of the Department of Clinical Investigation, group director for Clinical Research & Development in North America, director of the Department of Clinical Investigation and senior medical adviser of the Headquarters Medical Department.
Prior to his work at SmithKline Beecham, Dilly was the clinical project manager of Central Research with Pfizer Inc. and research fellow, Department of Physiology at Charing Cross Hospital Medical School, London.
Dilly holds a doctorate in cardiac physiology and a medical degree from the University of London.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Twelve of the currently marketed biotechnology products stem from Genentech science. Genentech markets seven products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange and Pacific Exchange under the symbol GNE.
# # #